Therapeutic effects elicited by the probiotic Lacticaseibacillus rhamnosus GG in children with atopic dermatitis. The results of the ProPAD trial

Laura Carucci, Rita Nocerino, Lorella Paparo, Francesca De Filippis, Serena Coppola, Veronica Giglio, Tommaso Cozzolino, Vincenzo Valentino, Giuseppina Sequino, Giorgio Bedogni, Roberto Russo, Danilo Ercolini, Roberto Berni Canani, Laura Carucci, Rita Nocerino, Lorella Paparo, Francesca De Filippis, Serena Coppola, Veronica Giglio, Tommaso Cozzolino, Vincenzo Valentino, Giuseppina Sequino, Giorgio Bedogni, Roberto Russo, Danilo Ercolini, Roberto Berni Canani

Abstract

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting up to 20% of the pediatric population associated with alteration of skin and gut microbiome. Probiotics have been proposed for AD treatment. The ProPAD study aimed to investigate the therapeutic effects of the probiotic Lacticaseibacillus rhamnosus GG (LGG) in children with AD.

Methods: In total, 100 AD patients aged 6-36 months were enrolled in a randomized, double-blind, controlled trial to receive placebo (Group A) or LGG (1 x 1010 CFU/daily) (Group B) for 12 weeks. The primary outcome was the evaluation of the efficacy of LGG supplementation on AD severity comparing the Scoring Atopic Dermatitis (SCORAD) index at baseline (T0) and at 12-week (T12). A reduction of ≥8.7 points on the SCORAD index was considered as minimum clinically important difference (MCID). The secondary outcomes were the SCORAD index evaluation at 4-week (T16) after the end of LGG treatment, number of days without rescue medications, changes in Infant Dermatitis Quality Of Life questionnaire (IDQOL), gut microbiome structure and function, and skin microbiome structure.

Results: The rate of subjects achieving MCID at T12 and at T16 was higher in Group B (p < .05), and remained higher at T16 (p < .05)The number of days without rescue medications was higher in Group B. IDQOL improved at T12 in the Group B (p < .05). A beneficial modulation of gut and skin microbiome was observed only in Group B patients.

Conclusions: The probiotic LGG could be useful as adjunctive therapy in pediatric AD. The beneficial effects on disease severity and quality of life paralleled with a beneficial modulation of gut and skin microbiome.

Trial registration: ClinicalTrials.gov NCT03863418.

Keywords: butyrate; gut microbiome; infant dermatitis quality of life questionnaire (IDQOL); scoring atopic dermatitis (SCORAD) index; skin microbiome.

Conflict of interest statement

The authors have no conflict of interest to declare.

© 2022 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Figures

FIGURE 1
FIGURE 1
The design of PROPAD Trial. * At T12. ** At T4 and T8
FIGURE 2
FIGURE 2
The flow of patients evaluated for the PROPAD Trial
FIGURE 3
FIGURE 3
The result of the main study outcome: the rate of children with atopic dermatitis achieving the minimum clinically important difference of ≥8.7 units for the SCORAD index. Placebo = Group A; LGG = Group B. Error bars: 95.00% CI. * Group A vs. Group B, p < .05.
FIGURE 4
FIGURE 4
The SCORAD index pattern during the trial. (Panel A) Change in SCORAD index from baseline (T0) to the end of study period (T16) in the two study groups. Group A = placebo, group B = LGG. Error bars: ±1.00 SE. *Group A vs. Group B, p < .05. Other significant differences: T0 vs. T8 Group A, p < .05; T0 vs. T8 Group B, p < .05; T0 vs. T12, Group B, p < .05; T0 vs. T16 Group A, p < 0.05; T0 vs. T16 Group B, p < .05; T4 vs. T12 Group B, p < .05; T4 vs. T16 Group B, p < .05. (Panel B) The atopic dermatitis severity pattern, evaluated through the SCORAD index, into the two study groups.
FIGURE 5
FIGURE 5
The modulation of the gut and skin microbiome in the two study groups. (Panel A) Butyrate concentration in fecal samples of subjects enrolled in the two study groups at baseline (T0) and after 12‐week (T12). Placebo = Group A, LGG = Group B. (Panel B) Skin microbiome composition at genus level in children receiving placebo (Group A) and in children receiving LGG (Group B) in the affected and unaffected skin area. ns, not significant difference; *p < .05; **p < .001.

References

    1. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345‐360.
    1. Kader HA, Azeem M, Jwayed SA, et al. Current insights into immunology and novel therapeutics of atopic dermatitis. Cell. 2021;10(6):1392.
    1. Luger T, Amagai M, Dreno B, et al. Atopic dermatitis: role of the skin barrier, environment, microbiome, and therapeutic agents. J Dermatol Sci. 2021;102(3):142‐157.
    1. Park JH, Um JI, Lee BJ, et al. Encapsulated Bifidobacterium bifidum potentiates intestinal IgA production. Cell Immunol. 2002;219(1):22‐27.
    1. Krutmann J. Pre‐ and probiotics for human skin. J Dermatol Sci. 2009;54(1):1‐5.
    1. Lopez‐Santamarina A, Gonzalez EG, Lamas A, Mondragon ADC, Regal P, Miranda JM. Probiotics as a possible strategy for the prevention and treatment of allergies. A narrative review. Foods. 2021;10(4):701.
    1. De Pessemier B, Grine L, Debaere M, Maes A, Paetzold B, Callewaert C. Gut‐skin Axis: current knowledge of the interrelationship between microbial dysbiosis and skin conditions. Microorganisms. 2021;9(2):353.
    1. Rusu E, Enache G, Cursaru R, et al. Prebiotics and probiotics in atopic dermatitis. Exp Ther Med. 2019;18(2):926‐931.
    1. Segers ME, Lebeer S. Towards a better understanding of Lactobacillus rhamnosus GG‐‐host interactions. Microb Cell Fact. 2014;13(Suppl 1):S7.
    1. Rautava S, Kainonen E, Salminen S, Isolauri E. Maternal probiotic supplementation during pregnancy and breast‐feeding reduces the risk of eczema in the infant. J Allergy Clin Immunol. 2012;130(6):1355‐1360.
    1. Lebeer S, Claes I, Tytgat HL, et al. Functional analysis of Lactobacillus rhamnosus GG pili in relation to adhesion and immunomodulatory interactions with intestinal epithelial cells. Appl Environ Microbiol. 2012;78(1):185‐193.
    1. Nermes M, Kantele JM, Atosuo TJ, Salminen S, Isolauri E. Interaction of orally administered Lactobacillus rhamnosus GG with skin and gut microbiota and humoral immunity in infants with atopic dermatitis. Clin Exp Allergy. 2011;41(3):370‐377.
    1. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr. 2003;36(2):223‐227.
    1. Isolauri E, Arvola T, Sütas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. Clin Exp Allergy. 2000;30(11):1604‐1610.
    1. Wollenberg A, Barbarot S, Bieber T, et al. Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657‐682.
    1. Wollenberg A, Barbarot S, Bieber T, et al. Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850‐878.
    1. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European task force on atopic dermatitis. Dermatology. 1993;186(1):23‐31.
    1. Lewis‐Jones MS, Finlay AY, Dykes PJ. The Infants' dermatitis quality of life index. Br J Dermatol. 2001;144(1):104‐110.
    1. Basra MK, Gada V, Ungaro S, Finlay AY, Salek SM. Infants' dermatitis quality of life index: a decade of experience of validation and clinical application. Br J Dermatol. 2013;169(4):760‐768.
    1. Corsello G, Carta M, Marinello R, et al. Preventive effect of Cow's Milk fermented with Lactobacillus paracasei CBA L74 on common infectious diseases in children: a multicenter randomized controlled trial. Nutrients. 2017;9(7):669.
    1. Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99‐106.
    1. Berni Canani R, De Filippis F, Nocerino R, et al. Specific signatures of the gut microbiota and increased levels of butyrate in children treated with fermented Cow's Milk containing heat‐killed lactobacillus paracasei CBA L74. Appl Environ Microbiol. 2017;83(19):e01206‐17.
    1. Human Microbiome Project Consortium . Structure, function, and diversity of the healthy human microbiome. Nature. 2012;486(7402):207‐214.
    1. Fierer N, Lauber CL, Zhou N, McDonald D, Costello EK, Knight R. Forensic identification using skin bacterial communities. Proc Natl Acad Sci USA. 2010;107(14):6477‐6481.
    1. Meisel JS, Hannigan GD, Tyldsley AS, et al. Skin microbiome surveys are strongly influenced by experimental design. J Invest Dermatol. 2016;136(5):947‐956.
    1. Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37(8):852‐857.
    1. D'Elios S, Trambusti I, Verduci E, et al. Probiotics in the prevention and treatment of atopic dermatitis. Pediatr Allergy Immunol. 2020;31(Suppl 26):43‐45.
    1. Fölster‐Holst R, Müller F, Schnopp N, et al. Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. Br J Dermatol. 2006;155(6):1256‐1261.
    1. Brouwer ML, Wolt‐Plompen SA, Dubois AE, et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo‐controlled trial. Clin Exp Allergy. 2006;36(7):899‐906.
    1. Grüber C, Wendt M, Sulser C, et al. Randomized, placebo‐controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy. Allergy. 2007;62(11):1270‐1276.
    1. Viljanen M, Kuitunen M, Haahtela T, Juntunen‐Backman K, Korpela R, Savilahti E. Probiotic effects on faecal inflammatory markers and on faecal IgA in food allergic atopic eczema/dermatitis syndrome infants. Pediatr Allergy Immunol. 2005;16(1):65‐71.
    1. Pachacama López AF, Tapia Portilla MF, Moreno‐Piedrahíta Hernández F, Palacios‐Álvarez S. Probiotics to reduce the severity of atopic dermatitis in pediatric patients: a systematic review and meta‐analysis. Actas Dermo‐Sifili. 2021;112(10):881‐890.
    1. Kim SO, Ah YM, Yu YM, Choi KH, Shin WG, Lee JY. Effects of probiotics for the treatment of atopic dermatitis: a meta‐analysis of randomized controlled trials. Ann Allergy Asthma Immunol. 2014;113(2):217‐226.
    1. Muzzolon M, Imoto RR, Canato M, Abagge KT, de Carvalho VO. Educational intervention and atopic dermatitis: impact on quality of life and treatment. Asia Pac Allergy. 2021;11(2):e21.
    1. Weston S, Halbert A, Richmond P, Prescott SL. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child. 2005;90(9):892‐897.
    1. Kim JE, Kim HS. Microbiome of the skin and gut in atopic dermatitis (AD): understanding the pathophysiology and finding novel management strategies. J Clin Med. 2019;8(4):444.
    1. Song H, Yoo Y, Hwang J, Na YC, Kim HS. Faecalibacterium prausnitzii subspecies‐level dysbiosis in the human gut microbiome underlying atopic dermatitis. J Allergy Clin Immunol. 2016;137(3):852‐860.
    1. Park DH, Kim JW, Park HJ, Hahm DH. Comparative analysis of the microbiome across the gut‐skin Axis in atopic dermatitis. Int J Mol Sci. 2021;22(8):4228.
    1. Salem I, Ramser A, Isham N, Ghannoum MA. The gut microbiome as a major regulator of the gut‐skin Axis. Front Microbiol. 2018;9:1459.
    1. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short‐chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569‐573.
    1. Plöger S, Stumpff F, Penner GB, et al. Microbial butyrate and its role for barrier function in the gastrointestinal tract. Ann N Y Acad Sci. 2012;1258:52‐59.
    1. Zhu TH, Zhu TR, Tran KA, Sivamani RK, Shi VY. Epithelial barrier dysfunctions in atopic dermatitis: a skin‐gut‐lung model linking microbiome alteration and immune dysregulation. Br J Dermatol. 2018;179(3):570‐581.
    1. Coppola S, Avagliano C, Sacchi A, et al. Potential clinical applications of the postbiotic butyrate in human skin diseases. Molecules. 2022;27(6):1849.
    1. Candela M, Rampelli S, Turroni S, et al. Unbalance of intestinal microbiota in atopic children. BMC Microbiol. 2012;12:95.
    1. Penders J, Stobberingh EE, van den Brandt PA, Thijs C. The role of the intestinal microbiota in the development of atopic disorders. Allergy. 2007;62(11):1223‐1236.
    1. Kim HK, Rutten NB, Besseling‐van der Vaart I, et al. Probiotic supplementation influences faecal short chain fatty acids in infants at high risk for eczema. Benef Microbes. 2015;6(6):783‐790.
    1. Nylund L, Nermes M, Isolauri E, Salminen S, de Vos WM, Satokari R. Severity of atopic disease inversely correlates with intestinal microbiota diversity and butyrate‐producing bacteria. Allergy. 2015;70(2):241‐244.
    1. Lee E, Lee SY, Kang MJ, et al. Clostridia in the gut and onset of atopic dermatitis via eosinophilic inflammation. Ann Allergy Asthma Immunol. 2016;117(1):91‐92.
    1. Climent E, Martinez‐Blanch JF, Llobregat L, et al. Changes in gut microbiota correlates with response to treatment with probiotics in patients with atopic dermatitis. A post hoc analysis of a clinical trial. Microorganisms. 2021;9(4):854.
    1. Berni Canani R, Sangwan N, Stefka AT, et al. Lactobacillus rhamnosus GG‐supplemented formula expands butyrate‐producing bacterial strains in food allergic infants. ISME J. 2016;10(3):742‐750.
    1. Belzer C, Chia LW, Aalvink S, et al. Microbial metabolic networks at the mucus layer Lead to diet‐independent butyrate and vitamin B12 production by intestinal symbionts. MBio. 2017;8(5):e00770‐17.
    1. Fujimura KE, Sitarik AR, Havstad S, et al. Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. Nat Med. 2016;22(10):1187‐1191.
    1. Lee MJ, Kang MJ, Lee SY, et al. Perturbations of gut microbiome genes in infants with atopic dermatitis according to feeding type. J Allergy Clin Immunol. 2018;141(4):1310‐1319.
    1. Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850‐859.
    1. Dekio I, Sakamoto M, Hayashi H, Amagai M, Suematsu M, Benno Y. Characterization of skin microbiota in patients with atopic dermatitis and in normal subjects using 16S rRNA gene‐based comprehensive analysis. J Med Microbiol. 2007;56(Pt 12):1675‐1683.
    1. Teo WY, Chan MY, Lam CM, Chong CY. Skin manifestation of Stenotrophomonas maltophilia infection‐‐a case report and review article. Ann Acad Med Singapore. 2006;35(12):897‐900.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi